---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-204944"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:26:20.693732+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IDEAYA reports positive Phase 2/3 darovasertib trial; Q1 net loss $98.5M, cash $973M

## Summary
- Phase 2/3 OptimUM-02 met primary endpoint: 58% risk reduction in PFS (HR 0.42, p<0.0001), median PFS 6.9 vs 3.1 months.
- NDA submission for darovasertib under FDA RTOR planned H2 2026; complete data at ASCO 2026.
- Cash equivalents and marketable securities $972.9M as of March 31, 2026; runway unchanged into 2030.
- Net loss for Q1 2026 was $98.5M vs $83.3M in Q4 2025; R&D expenses $95.7M.
- Appointed Dr. Theodora Ross as Chief Development Officer in February 2026.

## SEC filing metadata
- accession: 0001193125-26-204944
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312526204944/0001193125-26-204944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312526204944/idya-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-204944
- JSON: https://secwatch.observer/filing/0001193125-26-204944.json
- Plain text: https://secwatch.observer/filing/0001193125-26-204944.txt

## Source-grounded claims
- claim_id: b507fd5e8aca1639b9892d492d85c4a1882a062f
  claim: IDEAYA Biosciences, Inc. reported financial results for the first quarter ended March 31, 2026.
  evidence_excerpt: On May 5, 2026, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1676725/000119312526204944/0001193125-26-204944-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.